“Lastly, I would be lying if I didn't say that the details around the China announcement weren't a bit disappointing.”
Your expectations were to high, that’s the problem. This is an early NBA regarding indications that aren’t approved here in the U.S. or in China (Cancer and the corona virus). Information regarding an upfront payment, milestone payments and/or revenue sharing don’t exist yet like they did with the Vyera deal for HIV.
Bottom line: we as CYDY investors should be excited to test leronlimab in Corona Virus patients but we should taper our expectations until results come back. I’m also unsure if finalization of a deal regarding cancer will progress until there is further data, BTD approval, and/or FDA approval. I guess it’s possible that the CFDA could approve leronlimab for use in cancer patients in China before the U.S. does, but that still appears to be some time away.
Your expectations were to high, that’s the problem. This is an early NBA regarding indications that aren’t approved here in the U.S. or in China (Cancer and the corona virus). Information regarding an upfront payment, milestone payments and/or revenue sharing don’t exist yet like they did with the Vyera deal for HIV.
Bottom line: we as CYDY investors should be excited to test leronlimab in Corona Virus patients but we should taper our expectations until results come back. I’m also unsure if finalization of a deal regarding cancer will progress until there is further data, BTD approval, and/or FDA approval. I guess it’s possible that the CFDA could approve leronlimab for use in cancer patients in China before the U.S. does, but that still appears to be some time away.
